Fibroblast growth factor-21 and the beneficial effects of long-chain n-3 polyunsaturated fatty acids

Lipids

Volumn 49, Issue 11, 2014, Pages 1081-1089

  Villarroya, Joan ^a,b   Flachs, Pavel ^c   Redondo Angulo, Ibon ^a,d   Giralt, Marta ^a,d   Medrikova, Dasa ^c   Villarroya, Francesc ^a,d   Kopecky, Jan ^c   Planavila, Anna ^a,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

Fibroblast growth factor 21; Long chain n 3 polyunsaturated fatty acids

Indexed keywords

ADIPONECTIN; CORN OIL; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; INSULIN; INTERLEUKIN 6; LEPTIN; LONG CHAIN FATTY ACID; MESSENGER RNA; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TRIACYLGLYCEROL; UNCOUPLING PROTEIN 1; FIBROBLAST GROWTH FACTOR; ION CHANNEL; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL UNCOUPLING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG MEGADOSE; GENE EXPRESSION; GENE TARGETING; GLUCOSE BLOOD LEVEL; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULINEMIA; LIPID DIET; LONG TERM CARE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; SHORT COURSE THERAPY; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; DRUG EFFECTS; GENETICS; LIVER; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; WEIGHT GAIN;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CORN OIL; DIET, HIGH-FAT; FATTY ACIDS, OMEGA-3; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; INSULIN; ION CHANNELS; LIVER; MALE; MICE, INBRED C57BL; MITOCHONDRIAL PROTEINS; PPAR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRIGLYCERIDES; UP-REGULATION; WEIGHT GAIN;

EID: 84910643169     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-014-3948-x     Document Type: Article

References (25)

1. Flachs P, Rossmeisl M, Bryhn M, Kopecky J (2009) Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci (Lond) 116:1-16
2. Mori TA, Bao DQ, Burke V, Puddey IB, Watts GF, Beilin LJ (1999) Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects. Am J Clin Nutr 70:817-825
3. Flachs P, Horakova O, Brauner P, Rossmeisl M, Pecina P, Franssen-van HN et al (2005) Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce beta-oxidation in white fat. Diabetologia 48:2365-2375
4. Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L et al (2005) Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 310:314-317
5. Jelenik T, Rossmeisl M, Kuda O, Jilkova ZM, Medrikova D, Kus V et al (2010) AMP-activated protein kinase alpha2 subunit is required for the preservation of hepatic insulin sensitivity by n-3 polyunsaturated fatty acids. Diabetes 59:2737-2746
6. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ et al (2012) Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 148:556-567
7. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627-1635
8. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y et al (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018-6027
9. Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T et al (2011) Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem 286:12983-12990
10. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V et al (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5:415-425
11. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R et al (2007) BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 104:7432-7437
12. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426-437
13. Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F (2010) Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab 11:206-212
14. Flachs P, Ruhl R, Hensler M, Janovska P, Zouhar P, Kus V et al (2011) Synergistic induction of lipid catabolism and anti-inflammatory lipids in white fat of dietary obese mice in response to calorie restriction and n-3 fatty acids. Diabetologia 54:2626-2638
15. Horakova O, Medrikova D, van Schothorst EM, Bunschoten A, Flachs P, Kus V et al (2012) Preservation of metabolic flexibility in skeletal muscle by a combined use of n-3 PUFA and rosiglitazone in dietary obese mice. PLoS ONE 7:e43764
16. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9:327-338
17. Diaz-Delfin J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F (2012) TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153:4238-4245
18. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F et al (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246-1253
19. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS et al (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59:2781-2789
20. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M et al (2013) Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 17:779-789
21. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X et al (2010) Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 53:934-940
22. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM et al (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139:456-463
23. Yang C, Lu W, Lin T, You P, Ye M, Huang Y et al (2013) Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol 13:67
24. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS et al (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 94:4318-4323
25. Galman C, Lundasen T, Kharitonenkov A, Bina HA, Eriksson M, Hafstrom I et al (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 8:169-174